Covid-19 roundup: Plant-based shot proves safe, 71% ef­fi­ca­cious in PhI­II; Bourla ex­pects an­tivi­ral to launch this month

Que­bec-based Med­ica­go and its ad­ju­vant part­ner Glax­o­SmithK­line said Tues­day that their plant-based Covid-19 vac­cine can­di­date proved to be 71% ef­fi­ca­cious against all vari­ants of SARS-CoV-2 in a Phase III tri­al of more than 24,000 adults in Cana­da, the US, UK, Mex­i­co, Ar­genti­na and Brazil.

In ad­di­tion to show­ing 75% ef­fi­ca­cy against the Delta vari­ant specif­i­cal­ly, the com­pa­nies al­so said the vac­cine proved to be gen­er­al­ly safe, with no se­ri­ous ad­verse events re­port­ed and re­ac­to­genic­i­ty gen­er­al­ly be­ing mild to mod­er­ate. The re­sults mean that a reg­u­la­to­ry sub­mis­sion will be filed with Health Cana­da im­mi­nent­ly, they said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER